Acadia Pharmaceuticals INC 8-K filings

Acadia Pharmaceuticals stockholders approved an increase of 5,209,670 shares for the 2024 Equity Incentive Plan and elected three Class I directors.

Acadia Pharmaceuticals reported $268 million in Q1 2026 revenue, driven by strong DAYBUE sales and reaffirmed full-year guidance.

Acadia Pharmaceuticals reported strong fourth quarter and full year 2025 financial results, surpassing $1 billion in annual revenue for the first time, driven by NUPLAZID and DAYBUE sales.

Acadia Pharmaceuticals Inc. announced at the J.P. Morgan Healthcare Conference that it anticipates 2025 net sales will exceed $1 billion, aligning with previous guidance.

Acadia Pharmaceuticals announced robust third-quarter 2025 financial results, exceeding $1 billion in year-to-date sales and raising full-year revenue guidance.

Acadia Pharmaceuticals Inc. announced the resignation of Daniel B. Soland from its Board of Directors and Nominating and Corporate Governance Committee, effective October 30, 2025.

Acadia Pharmaceuticals reported strong second-quarter 2025 financial results with total revenues up 9% year-over-year, driven by growth in NUPLAZID and DAYBUE sales, and raised its NUPLAZID sales guidance.

Acadia Pharmaceuticals Inc. announced that the U.S. Court of Appeals for the Federal Circuit affirmed the validity of its crucial NUPLAZID (pimavanserin) '740 composition of matter patent, upholding a prior District Court decision against MSN Laboratories.

Acadia Pharmaceuticals Inc. announced the final voting results from its 2025 Annual Meeting of Stockholders, confirming the re-election of three Class III directors, advisory approval of executive compensation, and ratification of Ernst & Young LLP as independent auditors.

Acadia Pharmaceuticals enters into a new lease agreement for executive office space in Princeton, NJ, and wins a key patent infringement case.

Acadia Pharmaceuticals announces a 19% year-over-year increase in total revenue for Q1 2025, driven by strong sales of NUPLAZID and DAYBUE, and accelerates the timeline for its COMPASS PWS Phase 3 study.

Acadia Pharmaceuticals' board of directors has adopted amended and restated bylaws, effective April 15, 2025, modifying various aspects of corporate governance.

Acadia Pharmaceuticals announces positive Q4 and full-year 2024 financial results, highlighted by a 32% increase in total net product sales and provides revenue guidance for 2025.

Acadia Pharmaceuticals finalized the sale of its Rare Pediatric Disease Priority Review Voucher for $150 million, with a portion of the proceeds going to Neuren Pharmaceuticals.

Acadia Pharmaceuticals has announced the involuntary termination of its Chief Operating Officer, Brendan Teehan, effective immediately, with a transition period until the end of the year.

Acadia Pharmaceuticals announced a profitable third quarter in 2024, driven by strong sales of NUPLAZID and DAYBUE, and updated its full-year financial guidance.

Acadia Pharmaceuticals has announced the departure of CEO Stephen R. Davis, effective September 23, 2024, and the appointment of Catherine Owen Adams as his successor.

Acadia Pharmaceuticals announced a 46% year-over-year increase in total net product sales for the second quarter of 2024, reaching $242.0 million.

Acadia Pharmaceuticals held its 2024 Annual Meeting where stockholders approved the 2024 Equity Incentive Plan and elected three Class II directors.

Acadia Pharmaceuticals announced first-quarter 2024 financial results, showcasing significant revenue growth driven by the successful launch of DAYBUE and continued strong performance of NUPLAZID.

Acadia Pharmaceuticals' Phase 3 ADVANCE-2 trial of pimavanserin for negative symptoms of schizophrenia did not meet its primary endpoint.

Acadia Pharmaceuticals announced a 40% revenue increase for 2023, primarily driven by the launch of DAYBUE and continued growth of NUPLAZID.

Acadia Pharmaceuticals has announced that Austin D. Kim, Executive Vice President, General Counsel and Secretary, will be leaving the company to pursue other opportunities.